ArticleOncogene2024
PRAME induces genomic instability in uveal melanoma.
Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- PRAME predicting outcome in uveal melanoma.The journal of pathology. Clinical research · 2026Article
- GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma.Cancer research · 2026Article
- A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma.Cancer research · 2026Article
- Prognostic value of PRAME gene promoter methylation and expression in hepatocellular carcinoma.Clinical epigenetics · 2026Article
- DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling.Translational lung cancer research · 2026Article
- Shared PRAME epitopes are T-cell targets in NUT carcinoma.Journal for immunotherapy of cancer · 2026Article
- Identification of circRNA/lncRNA-miRNA-Transcription Factor-mRNA Networks to Identify Potential Biomarkers in Response to Neoadjuvant Therapy for Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Identification of targetable epigenetic vulnerabilities for uveal melanoma.Cell death & disease · 2025Article
- Comprehensive molecular analysis of uveal melanoma identifies targets in tumor-intrinsic and tumor-extrinsic pathways.iScience · 2025Article
- Tumor antigen PRAME promotes melanoma growth by inactivating p53 through the SIRT1-DBC1 axis.Oncogene · 2025Article
- Dualistic Role of MITF in Uveal Melanoma: Defining Two Distinct Cellular Subpopulations With Prognostic and Therapeutic Implications.Investigative ophthalmology & visual science · 2025Article
- Therapeutic Opportunities in Melanoma Through PRAME Expression.Biomedicines · 2025Review
- Transfer of Oncologic Signals from Melanoma Cells to Benign Melanocytes by Circulating Tumor-Derived Extracellular Vesicles.The Journal of investigative dermatology · 2025Article
- Bispecific Antibodies in Solid Tumors: Advances and Challenges.International journal of molecular sciences · 2025Review
- A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma.bioRxiv : the preprint server for biology · 2025Article
- Article
- Combined immunohistochemistry of PRAME and p16 in the differentiation of melanocytic neoplasms, with a detailed focus on acral lesions.Diagnostic pathology · 2024Article
- Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives.Biomedicines · 2024Review
- Review
- Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes.Journal of clinical medicine · 2024Article
Corrections and comments
- Update of
Authors and funding
20 authors at 6 institutions in 2 countries.
Funding
Abstract
PRAME is a CUL2 ubiquitin ligase subunit that is normally expressed in the testis but becomes aberrantly overexpressed in many cancer types in association with aneuploidy and metastasis. Here, we show that PRAME is expressed predominantly in spermatogonia around the time of meiotic crossing-over in coordination with genes mediating DNA double strand break repair. Expression of PRAME in somatic cells upregulates pathways involved in meiosis, chromosome segregation and DNA repair, and it leads to increased DNA double strand breaks, telomere dysfunction and aneuploidy in neoplastic and non-neoplastic cells. This effect is mediated at least in part by ubiquitination of SMC1A and altered cohesin function. PRAME expression renders cells susceptible to inhibition of PARP1/2, suggesting increased dependence on alternative base excision repair pathways. These findings reveal a distinct oncogenic function of PRAME that can be targeted therapeutically in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.